| Literature DB >> 31982231 |
SallyAnne L DeNotta1, Thomas J Divers2.
Abstract
The gastrointestinal tract and liver comprise key components of the equine digestive system and together have important functions in metabolism, digestion, absorption, detoxification, and synthesis. Disorders of the gastrointestinal tract and liver are common in clinical practice and can cause a variety of clinical signs. Hematologic and biochemical analysis can be helpful for identifying organ dysfunction, narrowing down the differential diagnostic list, and monitoring progress and response to treatment. This article details hematologic and biochemical tests that are important in the evaluation of intestinal and hepatic diseases and reviews bloodwork trends frequently observed in adult horses affected by enteropathy or hepatopathy.Entities:
Keywords: Chemistry; Enteropathy; Hematology; Hepatopathy; Hyperammonemia
Mesh:
Year: 2020 PMID: 31982231 PMCID: PMC7127838 DOI: 10.1016/j.cveq.2019.11.004
Source DB: PubMed Journal: Vet Clin North Am Equine Pract ISSN: 0749-0739 Impact factor: 1.792
Fig. 1Ultrasonographic image obtained from the right fourteenth intercostal space of a 3-year-old standardbred gelding with RDC secondary to chronic phenylbutazone administration. The total protein and albumin concentrations were 2.9 g/dL and 0.7 g/dL, respectively, on an initial serum biochemistry panel. The right dorsal colon wall (blue callipers) is markedly thickened, measuring between 1.9 cm and 2.1 cm (normal <0.4 cm). The gelding was treated successfully with colloid replacement, misoprostol, gastroprotectants, and discontinuation of the phenylbutazone.
Serum biochemical enzymes commonly used to detect equine hepatic diseasea
| Hepatocellular Injury | Biliary Injury/Cholestasis | ||||
|---|---|---|---|---|---|
| Glutamate Dehydrogenase | Sorbitol Dehydrogenase | Aspartate Aminotransferase | γ-Glutamyltransferase | Alkaline Phosphatase | |
| ∼Half-life | 12–24 h | <12 h | 7 d | 3 d | 3 d |
| Sensitivity | +++ | +++ | +++ | ++++ | ++ |
| Specificity | +++ | ++++ | + | +++ | + |
| Stability | ++ | + | ++++ | ++++ | ++++ |
+, Lowest; ++++, highest.
a These are estimated numbers based on review of available reports.,,,,
Pertinent clinical pathologic findings for case 1
| Day 1 | Day 3 | Reference Interval | |
|---|---|---|---|
| HCT | 66 | 41 | 34%–46% |
| White blood cell count | 12.2 | 6.3 | 5.2–10.1 thou/μL |
| Neutrophils | 4.4 | 3.3 | 2.7–6.6 thou/μL |
| Band neutrophils | 3.2 | 0 | 0.0–0.1 thou/μL |
| Monocytes | 1.8 | 0.8 | 0.0–0.6 thou/μL |
| Platelets | Adequate | Adequate | 94–232 thou/μL |
| Sodium | 115 | 132 | 134–142 mEq/L |
| Potassium | 3.2 | 3.2 | 2.4–4.8 mEq/L |
| Chloride | 69 | 106 | 95–104 mEq/L |
| Bicarbonate | 9 | 19 | 24–31 mEq/L |
| UN | 84 | 24 | 10–22 mg/dL |
| Creatinine | 5.5 | 1.4 | 0.8–1.5 mg/dL |
| Total protein | 6.3 | 3.0 | 5.4–7.0 g/dL |
| Albumin | 2.3 | 1.5 | 2.9–3.6 g/dL |
| 9.16 | 1.6 | <1.5 mmol/L | |
| Ammonia | 1495 (day 2) | 695 | <150 μg/dL |
Platelet clumping noted on smear precluded quantification.
Pertinent clinical pathologic findings for case 2
| Day 1 | Day 3 | Day 5 | Reference Interval | |
|---|---|---|---|---|
| Packed cell volume | 43 | 42 | 42 | 34%–46% |
| Total solids (by refractometer) | 7.2 | 6.9 | 6.8 | 5.2–7.8 g/dL |
| pH (venous) | 7.29 | 7.35 | — | 7.32–7.43 |
| Bicarbonate | 20 | 26 | 26 | 25–32 mEq/L |
| 3.5 | 1.8 | — | 0.8–1.8 mmol/L | |
| Creatinine | 2.2 | 1.6 | 1.5 | 0.8–2.0 mg/dL |
| CK | 57,040 | 21,984 | 1142 | 142–548 U/L |
| AST | 13,030 | 10,780 | 4474 | 199–374 U/L |
| SDH | 362 | 118 | 5 | 0–11 U/L |
| GGT | 77 | 146 | 103 | 8–29 U/L |
| Total bilirubin | 6.2 | 2.6 | 1.9 | 0.5–2.1 mg/dL |
| Direct bilirubin | 0.7 | 0.3 | 0.2 | 0.1–0.3 mg/dL |
| Triglycerides | 1929 | 75 | 27 | 14–65 mg/dL |